Rytmonorm Tablets

Rytmonorm Tablets is used for: Supraventricular and ventricular arrhythmias, Atrial Fibrillation/Flutter

Oral Supraventricular and ventricular arrhythmias, Atrial Fibrillation/Flutter Adult: For immediate-release tablet: Usual initial doses: 150 mg tid, may increase at intervals of 3-4 days up to 300 mg tid. Dose reduction is recommended in patients weighing <70 kg. Elderly: Dose reduction is recommended. Hepatic impairment: Dose reduction is recommended.

Safety and efficacy not established

Should be taken with food. Take after meals. Swallow whole, do not chew/crush.

Uncontrolled heart failure, marked hypotension, severe bradycardia and heart block, conduction abnormalities, cardiogenic shock, myasthenia gravis.

Severe pulmonary obstructive diseases, CHF, cardiac pacemaker, impaired renal/hepatic function, pregnancy, lactation, elderly. Correct electrolyte disturbances before starting treatment. May worsen heart failure in patients with preexisting organic heart disease. May worsen or cause new severe ventricular arrhythmias e.g. ventricular tachycardia or fibrillation. May aggravate electrically induced ventricular tachycardia in some patients. Lactation: Crosses into breast milk; discontinue drug or do not nurse

Pregnancy There are no studies in pregnant women; available data from published case reports and several decades of postmarketing experience with use in pregnancy have not identified any drug-associated risks of miscarriage, birth defects, or adverse maternal or fetal outcomes; untreated arrhythmias during pregnancy may pose a risk to pregnant woman and fetus; the drug and its metabolite, 5-OH-propafenone, cross the placenta in humans Incidence of VT is increased and may be more symptomatic during pregnancy; ventricular arrhythmias most often occur in pregnant women with underlying cardiomyopathy, congenital heart disease, valvular heart disease, or mitral valve prolapse; breakthrough arrhythmias may occur during pregnancy, as therapeutic treatment levels may be difficult to maintain due to increased volume of distribution and increased drug metabolism inherent in pregnant state The drug and its metabolite have been shown to cross placenta; adverse reactions such as fetal/neonatal arrhythmias have been associated with use of other antiarrhythmic agents by pregnant women; fetal/neonatal monitoring for signs and symptoms of arrhythmia is recommended during and after treatment of pregnant women Animal data In animal studies, propafenone was not teratogenic; at maternally toxic doses (ranging from 2 to 6 times maximum recommended human dose [MRHD]), there was evidence of adverse developmental outcomes when administered to pregnant rabbits and rats during organogenesis or when administered to pregnant rats during mid-gestation through weaning of their offspring Infertility Based on human and animal studies, may transiently impair spermatogenesis in males; reversible decreases in spermatogenesis have been demonstrated in monkeys, dogs, and rabbits after lethal or near-lethal intravenous doses of the drug Labor or Delivery Risk of arrhythmias may increase during labor and delivery; patients should be monitored continuously for arrhythmias during labor and delivery Lactation Propafenone and its active metabolite, 5-OH-propafenone, are present in human milk, but levels are likely to be low; there are no data on effects on breastfed infant or on milk production The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for propafenone and any potential adverse effects on breastfed infant from propafenone or from underlying maternal condition

Effect may be potentiated by local anesth, beta-blockers, TCA. May increase plasma level of propranolol, metoprolol, desipramine, cyclosporin, digoxin, theophylline. Plasma conc may rise when taken simultaneously w/ cimetidine or quinidine. May enhance effect of anticoagulant. Simultaneous administration w/ phenobarb or rifamycin may decrease propafenone plasma conc, possibly in sub-therapeutic levels.

Side effects of Propafenone Hydrochloride : >10% Unusual taste (7-23%), Dizziness/lightheadedness (7-15%), N/V (3-11%) 1-10% Constipation (4-8%), Headache (2-6%), Intraventricular conduction delay (4%), Fatigue (6%), Blurred vision (3%), Weakness (3%), Dyspnea (2%), Wild complex tachycardia (2%), Bradycardia (2%), Palpitations (2%), Tremor (2%), Anorexia (2%), Diarrhea (2%), Ataxia (2%), 1°AV block (2-5%), Angina (5%), Palpitations (3%), CHF (2-3% ), Chest pain (2%), Bradyarrhythmia (2%), AF (1%), Bundle branch block (1%), 2nd degree AV block (1%), Hypotension (1%), Sinus arrest (1%) Frequency Not Defined Lethargy, Rash, Dyspepsia, Dry mouth, Agranulocytosis, Hepatotoxicity (rare), Systemic lupus erythematosus (rare), Bronchospasm (rare) Potentially Fatal: SA/AV or intraventricular blocks. Severe hypotension, especially in elderly.

Propafenone is a class 1C antiarrhythmic drug with local anaesthetic effects, and a direct stabilising action on myocardial membranes. The electrophysiological effect manifests itself in a reduction of upstroke velocity (Phase 0) of the monophasic action potential. In Purkinje fibers, and to a lesser extent myocardial fibers, propafenone reduces the fast inward current carried by sodium ions. Diastolic excitability threshold is increased and effective refractory period prolonged. Propafenone reduces spontaneous automaticity and depresses triggered activity.

Rytmonorm 300mg Tablets manufactured by ABBOTT GmbH & CO. KG. Its generic name is Propafenone Hydrochloride. Rytmonorm is availble in United Arab Emirates. Farmaco UAE drug index information on Rytmonorm Tablets is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.